New genetic variations discovered in KRAS wild‐type cetuximab resistant chinese colorectal cancer patients

  title={New genetic variations discovered in KRAS wild‐type cetuximab resistant chinese colorectal cancer patients},
  author={Changwen Jing and Ting Wang and Rong Ma and Haixia Cao and Zhuo Wang and Siwen Liu and Dan Chen and Junying Zhang and Yang Wu and Ying-nan Zhang and Jian-zhong Wu and Jifeng Feng},
  journal={Molecular Carcinogenesis},
  pages={478 - 491}
To perform a comprehensive genomic analysis of colorectal cancer (CRC) tumor to detect genetic variants and identify novel resistant mutations associated with cetuximab‐resistance in CRC patients. A retrospective study was performed using whole exome sequencing (WES) to identify common genetic factors from 22 cetuximab‐sensitive and 10 cetuximab‐resistant patients. In all 10 cetuximab‐resistant patients, we discovered there are 37 significantly mutated genes (SMGs). CYP4A11 was the most… 
Differential Expression Analysis Revealing CLCA1 to Be a Prognostic and Diagnostic Biomarker for Colorectal Cancer
The results of gene set enrichment analysis (GSEA) and immune infiltration analysis showed that CLCA1 was closely related to tumor metabolism and immune invasion of CRC and may be a candidate diagnostic and prognostic biomarker for CRC.
Multi-omics analysis to identify driving factors in colorectal cancer.
This study identified LRRC26 and REP15 as novel prognosis-related driving genes for CRC and may provide new insights into the molecular mechanisms of CRC.
Establishment of a Novel Combined Nomogram for Predicting the Risk of Progression Related to Castration Resistance in Patients With Prostate Cancer
The combined nomogram can be used to predict the individualized risk of progression related to castration resistance for PCa patients and has been preliminarily verified to have good predictive ability.


Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients
Novel genomic alterations are uncovered that elucidate the mechanisms of sensitivity and resistance to anti-EGFR therapy in metastatic CRC patients and show that PI3K/mTOR inhibition could rescue cetuximab resistance.
Primary Colorectal Cancers and Their Subsequent Hepatic Metastases Are Genetically Different: Implications for Selection of Patients for Targeted Treatment
The study indicates that the genetic characteristics of the hepatic metastases are different from those of the primary CRC tumor, and the choice of treatment in studies investigating targeted therapies should ideally be based on the genetic properties of the metastasis rather than on those ofThe primary tumor.
Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies
It is discovered that V EGFR2 is somatically mutated across tumor types and that VEGFR2 mutants can be oncogenic and control sensitivity/resistance to antiangiogenic drugs.
Discovery and saturation analysis of cancer genes across 21 tumor types
It is found that large-scale genomic analysis can identify nearly all known cancer genes in these cancer types and 33 genes that were not previously known to be significantly mutated in cancer, including genes related to proliferation, apoptosis, genome stability, chromatin regulation, immune evasion, RNA processing and protein homeostasis.
The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
A systematic approach to evaluating response to targeted therapies in human cancer is provided, new mechanisms of responsiveness to anti-EGFR therapies are highlighted, and new avenues for intervention in managing colorectal cancer are delineated.
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
The majority of advanced, treatment-resistant tumors across tumor types harbor biologically informative alterations, and the establishment of a clinical trial for WES of metastatic tumors with prospective follow-up of patients can help identify candidate predictive biomarkers of response.
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients
EGFR promoter hypermethylation, after confirmation in larger data set, may represent a valuable asset in further studies investigating EGFR as a therapeutic target in colorectal cancer.
Whole genome sequencing analysis for cancer genomics and precision medicine
Explosive advances in next‐generation sequencer (NGS) and computational analyses have enabled exploration of somatic protein‐altered mutations in most cancer types, with coding mutation data